Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Inventors

Marom, Ehud • Rubnov, Shai

Assignees

Mapi Pharma Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-RE49251-E1

Patent

Publication Date

2022-10-18

Expiration Date


Abstract

Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.

Core Innovation

The invention provides long-acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer in a sustained-release depot form. The depot is configured to release the salt over a duration of about one week to about six months. Certain embodiments utilize glatiramer acetate formulated in PLGA microparticles at specified active agent amounts and glatiramer acetate-to-PLGA weight ratios.

The compositions are formulated for prolonged drug release and parenteral treatment of multiple sclerosis. Formulations exhibit tunable in vitro release kinetics and demonstrate therapeutic activity in mouse experimental autoimmune encephalomyelitis models. The sustained-release characteristics allow extended dosing intervals relative to standard glatiramer dosage forms.

Claims Coverage

The claims identify four inventive features corresponding to four independent claims covering sustained-release glatiramer depot compositions and methods of treating multiple sclerosis.

Long-acting glatiramer salt depot composition

A long-acting parenteral pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer in a sustained-release depot form that releases a therapeutically effective amount over about one week to about six months.

Parenteral treatment of multiple sclerosis

Parenterally administering to a subject in need thereof a long-acting composition comprising a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer in a sustained-release depot form, releasing over about one week to about six months.

Multiple sclerosis treatment with specified glatiramer acetate and PLGA depot

Parenterally administering a sustained-release depot containing 20 mg to 750 mg of glatiramer acetate with a PLGA carrier at a glatiramer acetate-to-PLGA weight ratio from 1:5.2 to 1:15.9, releasing over one week to six months.

Specified glatiramer acetate and PLGA depot composition

A long-acting parenteral pharmaceutical composition containing 20 mg to 750 mg of glatiramer acetate in a sustained-release depot comprising a PLGA carrier at a glatiramer acetate-to-PLGA weight ratio ranging from 1:5.2 to 1:15.9.

The claims provide coverage for broad sustained-release glatiramer depot compositions and methods of treating multiple sclerosis, as well as specific glatiramer acetate and PLGA carrier formulations.

Stated Advantages

The depot provides prolonged release, with dosing intervals ranging from weekly to six-monthly.

The composition exhibits comparable or superior therapeutic efficacy relative to conventional daily injectable glatiramer acetate dosage forms.

The formulation provides a reduced incidence and/or severity of local or systemic side effects.

Documented Applications

Parenteral treatment of multiple sclerosis utilizing a sustained-release depot containing a pharmaceutically acceptable salt of glatiramer.

Subcutaneous and intramuscular administration of the depot formulations, including intramuscular injection of a microparticle suspension.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.